Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
暂无分享,去创建一个
T. Zimmerman | M. Dhodapkar | P. Richardson | S. Rajkumar | N. Callander | R. Orlowski | P. Voorhees | M. Rosenzweig | J. Zonder | B. Durie | S. Usmani | A. Hoering | S. Rajkumar | S. Ailawadhi | B. Lipe | J. Valent | R. Sexton | Sandi Hita
[1] M. Dimopoulos,et al. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. , 2020, JAMA oncology.
[2] N. Geller,et al. Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). , 2020 .
[3] B. Barlogie,et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) , 2020, Blood Cancer Journal.
[4] U. Mellqvist,et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 stud , 2020, The Lancet. Haematology.
[5] C. Hofmeister,et al. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] P. Voorhees,et al. Extramedullary multiple myeloma , 2019, Leukemia.
[7] Nisha S Joseph,et al. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone , 2019, Blood Cancer Journal.
[8] P. Sonneveld,et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study , 2019, The Lancet.
[9] H. Goldschmidt,et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. , 2019, The New England journal of medicine.
[10] Andre H Crepaldi,et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma , 2017, The New England journal of medicine.
[11] Sin-Ho Jung,et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] N. Munshi,et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.
[13] H. Goldschmidt,et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Jessica Katz,et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. , 2015, The New England journal of medicine.
[15] J. Miguel,et al. Defining and treating high-risk multiple myeloma , 2015, Leukemia.
[16] R. Orlowski,et al. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211 , 2015, Blood Cancer Journal.
[17] Hans Erik Johnsen,et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.
[18] S. Jagannath,et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] B. Pégourié,et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Jakubowiak,et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] B. Barlogie,et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling, and clinical outcome with Total Therapy protocols , 2012, Leukemia.
[22] John Crowley,et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. , 2011, Blood.
[23] D. Hose,et al. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone , 2011, Cancer.
[24] D. Esseltine,et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.
[25] B. Barlogie,et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. , 2010, Blood.
[26] N. Munshi,et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.
[27] F. Zhan,et al. CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma , 2008, Clinical Cancer Research.
[28] B. Barlogie,et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 , 2007, British journal of haematology.
[29] Emilie Flaberg,et al. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells , 2007, Molecular Cancer Therapeutics.
[30] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[31] Jeroen Kuipers,et al. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint , 2004, British journal of haematology.
[32] M. Rue,et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.
[33] Terry L. Smith,et al. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. , 1991, Annals of internal medicine.
[34] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.